Oruka Therapeutics, Inc. Cash Flow Statement
ORKA / Health Care|15 years of annual SEC 10-K data (FY2010-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Oruka Therapeutics, Inc. used $58M in operating cash flow and negative free cash flow of $58M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$83.7M | -$5.3M | -$19.3M | -$9.7M | -$5.5M | -$7.9M | -$18.5M | -$16.4M | -$11.4M | -$9.7M | -$6.9M | -$6.9M | -$4.3M | -$5.4M | -$8.4M |
| Depreciation & Amortization | $27.0K | $15.0K | $16.0K | $8.0K | $18.0K | $22.0K | $27.0K | $24.0K | $19.0K | $12.0K | $26.0K | $26.0K | $43.0K | $602.0K | $338.0K |
| Operating Cash Flow | -$57.8M | -$5.0M | -$18.8M | -$7.7M | -$4.8M | -$8.2M | -$17.5M | -$15.0M | -$10.5M | -$9.4M | -$5.3M | -$5.3M | -$4.1M | -$7.0M | -$8.3M |
| Capital Expenditures | $189.0K | $0 | $43.0K | $19.0K | $4.0K | $4.0K | $3.0K | $12.0K | $11.0K | $19.0K | $32.0K | $32.0K | $1.9M | $19.0K | $4.0K |
| Free Cash Flow | -$58.0M | -$5.0M | -$18.8M | -$7.7M | -$4.8M | -$8.2M | -$17.5M | -$15.0M | -$10.5M | -$9.4M | -$5.3M | -$5.3M | -$6.0M | -$7.0M | -$8.3M |